Beryl Drugs Limited

BSE: 524606
Beryl Drugs Limited - pharma in Indore, Madhya Pradesh, India. FY 2026 financials and compliance.
CIN L02423MP1993PLC007840 Incorporated 24 August 1993 ROC Gwalior HQ Indore, Madhya Pradesh, India
Active Listed - BSE: 524606 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹18.82 Cr
▼ 11% YoY
EBITDA · FY 2026
₹2.43 Cr
▼ 8.16% YoY
Net profit · FY 2026
₹42.48 Lakh
▼ 26.62% YoY
Authorised capital
₹10 Cr
Registered with MCA
Paid-up capital
₹5.07 Cr
Issued & subscribed
Open charges
₹5.75 Cr
Satisfied ₹7.09 Cr
Company age
33 yrs
Est. 1993
Employees · EPFO
22
Latest available

About Beryl Drugs Limited

Data last updated: 16 February 2026

Beryl Drugs Limited is a public limited company based in Indore, Madhya Pradesh, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 24 August 1993, the company has been in operation for over 33 years.

Registered with ROC Gwalior under CIN L02423MP1993PLC007840. Listed on BSE: 524606.

Capital: an authorised share capital of ₹10 Cr and a paid-up capital of ₹5.07 Cr. It is led by directors including Sudhir Sethi and Abhinav Naik.

Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: 133 Kanchan Bagh, Indore, Madhya Pradesh, India – 452001.

As per the financials filed for FY 2025, the company reported a revenue of ₹22.55 Cr, a decline of 17% compared to the previous year.

The company has a workforce of approximately 22 employees as per the latest available data.

The company is associated with 1 brand - Beryl Drugs. As per MCA filings, the company has open charges of ₹5.75 Cr and satisfied charges of ₹7.09 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website beryldrugs.com.

Company Details of Beryl Drugs Limited
CIN L02423MP1993PLC007840
Registration Number 007840
Incorporation Date 24 August 1993
ROC Gwalior
Listing Status Listed (BSE: 524606)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sanjay Sethi Managing Director Sudhir Sethi Director Abhinav Naik Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    beryldrugs.com
  • Social Media
  • Registered Address
    133 Kanchan Bagh, Indore, Madhya Pradesh, India – 452001
  • Industry
    Pharma, Drug Formulation & Development
Company report
Beryl Drugs Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Beryl Drugs Limited report

Financials, compliance, directors, charges, ownership and filings for Beryl Drugs Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Beryl Drugs Limited

Beryl Drugs Limited has one previous CIN (Corporate Identification Number): U02423MP1993PLC007840. The current CIN is L02423MP1993PLC007840, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L02423MP1993PLC007840 Current
U02423MP1993PLC007840 Previous

Associated Brands with Beryl Drugs Limited

Beryl Drugs Limited operates one associated brand: Beryl Drugs. These brands represent Beryl Drugs Limited's diversified market presence and brand portfolio.

Brand Description Website
Beryl Drugs
Pharmaceutical and allied healthcare products are manufactured for various supplies. beryldrugs.com

Business Activity of Beryl Drugs Limited

Beryl Drugs Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Beryl Drugs Limited

Beryl Drugs Limited is audited by Subhash Chand Jain Anurag & Associates (ICAI peer reviewed, certificate valid till 2027-03-31) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Subhash Chand Jain Anurag & Associates (ICAI peer reviewed, certificate valid till 2027-03-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Beryl Drugs Limited

Beryl Drugs Limited is currently managed by 8 directors, with 14 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Sudhir Sethi
Also directs: Beryl Drugs Limited
Director 12 Dec 2000 25 Years 6 Months Current
Abhinav Naik
Also directs: Beryl Drugs Limited, Beryl Securities Limited
Director 30 May 2019 7 Years 1 Months Current
Shreya Saraf
Also directs: Beryl Drugs Limited, Narmada Extrusions Limited
Director 30 May 2019 7 Years 1 Months Current
Sanjay Sethi
Also directs: Beryl Drugs Limited
Managing Director 12 Dec 2000 25 Years 6 Months Current
Shailendra Pathak
Also directs: Beryl Drugs Limited, Aminova Infusions Private Limited
Additional Director 03 Jan 2026 0 Years 6 Months Current
Neha Sarda
Also directs: Beryl Drugs Limited, Beryl Securities Limited, Recharge Trendd Setter Limited
Additional Director 03 Jan 2026 0 Years 6 Months Current
Showing 6 of 8 current directors. View all directors

Financials of Beryl Drugs Limited FY 2026 filings available

Beryl Drugs Limited reported revenue of ₹18.82 Cr (down 11% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹18.82 Cr ▼ 11%
Profit · FY 2026
₹42.48 Lakh ▼ 26.62%
EBITDA · FY 2026
₹2.43 Cr ▼ 8.16%
Revenue₹ Cr · Standalone0102030FY 2019: ₹13 Cr13FY 2019FY 2020: ₹13 Cr · -1.1% YoY12.8-1.1%FY 2020FY 2021: ₹14 Cr · +10% YoY14.1+10%FY 2021FY 2022: ₹15 Cr · +3.6% YoY14.6+3.6%FY 2022FY 2023: ₹27 Cr · +84.1% YoY26.9+84.1%FY 2023FY 2024: ₹27 Cr · -0.6% YoY26.7-0.6%FY 2024FY 2025: ₹21 Cr · -20.9% YoY21.1-20.9%FY 2025FY 2026: ₹19 Cr · -11% YoY18.8-11%FY 2026
Net Profit₹ Cr · Standalone-1-0.500.51FY 2019: ₹1 Cr0.6FY 2019FY 2020: ₹0 Cr · -91.9% YoY0-91.9%FY 2020FY 2021: ₹0 Cr · +400.2% YoY0.2+400.2%FY 2021FY 2022: ₹1 Cr (loss) · -375% YoY-0.7FY 2022FY 2023: ₹1 Cr · +216.3% YoY0.8+216.3%FY 2023FY 2024: ₹1 Cr · +0.3% YoY0.8+0.3%FY 2024FY 2025: ₹1 Cr · -24.7% YoY0.6-24.7%FY 2025FY 2026: ₹0 Cr · -26.6% YoY0.4-26.6%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year02.557.5Q1'25: ₹6 Cr6.2Q1'25Q2'25: ₹6 Cr5.6Q2'25Q3'25: ₹5 Cr5.3Q3'25Q4'25: ₹4 Cr4Q4'25Q1'26: ₹5 Cr · -23.3% YoY4.8-23.3%Q1'26Q2'26: ₹5 Cr · -8.8% YoY5.1-8.8%Q2'26Q3'26: ₹4 Cr · -28.9% YoY3.8-28.9%Q3'26Q4'26: ₹5 Cr · +29.1% YoY5.1+29.1%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue from Operations ₹18.82 Cr ₹21.15 Cr ₹26.73 Cr ₹26.89 Cr ₹14.6 Cr ₹14.09 Cr ₹12.82 Cr ₹12.96 Cr
Other Income ₹49 Lakh ₹1.41 Cr ₹39.51 Lakh ₹26.87 Lakh ₹16.49 Lakh ₹18.71 Lakh ₹23.31 Lakh ₹24.38 Lakh
Total Income ₹19.31 Cr ₹22.55 Cr ₹27.12 Cr ₹27.16 Cr ₹14.77 Cr ₹14.28 Cr ₹13.05 Cr ₹13.2 Cr
Cost of Materials Consumed ₹10.51 Cr ₹11.12 Cr ₹13.31 Cr ₹14.23 Cr ₹8.71 Cr ₹7.45 Cr ₹6.68 Cr ₹6.85 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹74.32 Lakh -₹33.7 Lakh -₹16.72 Lakh ₹31.25 Lakh -₹30.41 Lakh -₹3.27 Lakh -₹7 Lakh ₹12.95 Lakh
Employee Benefit Expense ₹2.53 Cr ₹2.21 Cr ₹1.93 Cr ₹1.7 Cr ₹1.31 Cr ₹1.18 Cr ₹96.53 Lakh ₹84.55 Lakh
Finance Costs ₹34.43 Lakh ₹52.97 Lakh ₹46.35 Lakh ₹41.56 Lakh ₹43.68 Lakh ₹46.57 Lakh ₹32.1 Lakh ₹14.61 Lakh
Depreciation & Amortisation ₹1.49 Cr ₹1.25 Cr ₹1.2 Cr ₹81.44 Lakh ₹1.09 Cr ₹1.27 Cr ₹65.94 Lakh ₹32.41 Lakh
Other Expenses ₹4.59 Cr ₹6.92 Cr ₹9.38 Cr ₹8.71 Cr ₹4.48 Cr ₹4.05 Cr ₹4.34 Cr ₹4.11 Cr
Total Expenses ₹18.72 Cr ₹21.69 Cr ₹26.12 Cr ₹26.17 Cr ₹15.72 Cr ₹14.38 Cr ₹12.89 Cr ₹12.41 Cr
Profit Before Exceptional Items & Tax ₹58.8 Lakh ₹86.57 Lakh ₹1.01 Cr ₹98.39 Lakh -₹95.03 Lakh -₹10.39 Lakh ₹15.79 Lakh ₹79.63 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹45.18 Lakh ₹0 ₹0
Profit Before Tax ₹58.8 Lakh ₹86.57 Lakh ₹1.01 Cr ₹98.39 Lakh -₹95.03 Lakh ₹34.79 Lakh ₹15.79 Lakh ₹79.63 Lakh
Total Tax Expense ₹16.32 Lakh ₹28.68 Lakh ₹24.11 Lakh ₹21.78 Lakh -₹29.13 Lakh ₹10.83 Lakh ₹11 Lakh ₹20.56 Lakh
Net Profit ₹42.48 Lakh ₹57.89 Lakh ₹76.86 Lakh ₹76.61 Lakh -₹65.9 Lakh ₹23.96 Lakh ₹4.79 Lakh ₹59.07 Lakh
Other Comprehensive Income -₹1.81 Lakh ₹16,000 ₹8.83 Lakh ₹67,000 ₹2.32 Lakh ₹6.43 Lakh ₹4.94 Lakh ₹27.03 Lakh
Total Comprehensive Income ₹40.67 Lakh ₹58.05 Lakh ₹85.69 Lakh ₹77.28 Lakh -₹63.58 Lakh ₹30.39 Lakh ₹9.73 Lakh ₹86.1 Lakh
EBITDA (computed) ₹2.43 Cr ₹2.64 Cr ₹2.67 Cr ₹2.21 Cr ₹57.3 Lakh ₹1.64 Cr ₹1.14 Cr ₹1.27 Cr
Basic EPS ₹0.30 ₹1.14 ₹1.52 ₹1.52 ₹-1.30 ₹0.47 ₹0.09 ₹1.16
Diluted EPS ₹0.30 ₹1.14 ₹1.52 ₹1.52 ₹-1.30 ₹0.47 ₹0.09 ₹1.16
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Total Assets ₹14.96 Cr ₹15.96 Cr ₹17.49 Cr ₹17.51 Cr ₹17.82 Cr ₹18.65 Cr ₹16.91 Cr ₹14.57 Cr
Non-current Assets ₹7.94 Cr ₹6.92 Cr ₹7.27 Cr ₹7.2 Cr ₹7.2 Cr ₹8.5 Cr ₹9.4 Cr ₹8.68 Cr
Current Assets ₹7.03 Cr ₹9.04 Cr ₹10.22 Cr ₹10.32 Cr ₹10.58 Cr ₹10.11 Cr ₹7.51 Cr ₹5.89 Cr
Property, Plant & Equipment ₹6.82 Cr ₹6 Cr ₹5.96 Cr ₹5.81 Cr ₹5.86 Cr ₹7.32 Cr ₹8.47 Cr ₹1.81 Cr
Inventories ₹3.13 Cr ₹1.9 Cr ₹1.26 Cr ₹1.05 Cr ₹2.98 Cr ₹2.27 Cr ₹1.16 Cr ₹76.38 Lakh
Trade Receivables ₹2.09 Cr ₹5.46 Cr ₹7.58 Cr ₹6.9 Cr ₹4.45 Cr ₹4.54 Cr ₹3.45 Cr ₹3.44 Cr
Cash & Equivalents ₹27.35 Lakh ₹81.44 Lakh ₹12.49 Lakh ₹28.31 Lakh ₹27.14 Lakh ₹45.21 Lakh ₹39.63 Lakh ₹9.98 Lakh
Equity (Net Worth) ₹9.89 Cr ₹9.5 Cr ₹8.92 Cr ₹8.07 Cr ₹7.29 Cr ₹7.93 Cr ₹7.63 Cr ₹7.53 Cr
Equity Share Capital ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr ₹5.09 Cr
Borrowings (Non-current) ₹0 ₹1.74 Cr ₹2.4 Cr ₹2.72 Cr ₹1.68 Cr ₹1.99 Cr ₹26.57 Lakh ₹21.07 Lakh
Borrowings (Current) ₹2.39 Cr ₹2.34 Cr ₹2.69 Cr ₹1.82 Cr ₹3.62 Cr ₹2.35 Cr ₹2.39 Cr ₹1.76 Cr
Total Debt (computed) ₹2.39 Cr ₹4.07 Cr ₹5.09 Cr ₹4.54 Cr ₹5.29 Cr ₹4.34 Cr ₹2.66 Cr ₹1.97 Cr
Current Liabilities ₹4.53 Cr ₹4.3 Cr ₹5.76 Cr ₹6.33 Cr ₹7.29 Cr ₹8.21 Cr ₹6.63 Cr ₹5.53 Cr
Total Liabilities ₹5.08 Cr ₹6.46 Cr ₹8.56 Cr ₹9.45 Cr ₹10.53 Cr ₹10.72 Cr ₹9.29 Cr ₹7.04 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹3.65 Cr ₹2.64 Cr ₹1.01 Cr ₹2.48 Cr -₹28.67 Lakh
Investing Cash Flow -₹2.16 Cr -₹39.7 Lakh -₹1.26 Cr -₹1.3 Cr ₹53.79 Lakh
Financing Cash Flow -₹2.03 Cr -₹1.55 Cr ₹8.83 Lakh -₹1.17 Cr -₹43.19 Lakh
Capital Expenditure ₹3.82 Cr ₹2.19 Cr ₹1.35 Cr ₹1.56 Cr ₹41.55 Lakh
Free Cash Flow (computed) -₹17.47 Lakh ₹45.16 Lakh -₹33.88 Lakh ₹91.7 Lakh -₹70.22 Lakh
Dividends Paid ₹0 ₹0 ₹0 ₹0 ₹0
Net Change in Cash -₹54.08 Lakh ₹68.96 Lakh -₹15.82 Lakh ₹1.18 Lakh -₹18.07 Lakh
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25
Revenue from Operations ₹5.13 Cr ₹3.78 Cr ₹5.12 Cr ₹4.79 Cr ₹3.97 Cr ₹5.31 Cr ₹5.61 Cr ₹6.25 Cr
Other Income ₹33.83 Lakh ₹7.36 Lakh ₹3.66 Lakh ₹4.15 Lakh ₹1.25 Cr ₹9.34 Lakh ₹3.1 Lakh ₹3.82 Lakh
Total Income ₹5.47 Cr ₹3.85 Cr ₹5.16 Cr ₹4.84 Cr ₹5.22 Cr ₹5.4 Cr ₹5.65 Cr ₹6.29 Cr
Cost of Materials Consumed ₹3.43 Cr ₹2.08 Cr ₹2.79 Cr ₹2.21 Cr ₹2.46 Cr ₹2.63 Cr ₹2.67 Cr ₹3.36 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹30.69 Lakh -₹4.53 Lakh -₹20.76 Lakh -₹18.34 Lakh ₹35.25 Lakh -₹79.41 Lakh ₹1.35 Lakh ₹9.11 Lakh
Employee Benefit Expense ₹62.9 Lakh ₹78.91 Lakh ₹57.68 Lakh ₹53.39 Lakh ₹59.44 Lakh ₹62.01 Lakh ₹50.13 Lakh ₹49.64 Lakh
Finance Costs ₹7.15 Lakh ₹9.17 Lakh ₹8.02 Lakh ₹10.09 Lakh ₹7.9 Lakh ₹12.04 Lakh ₹12.26 Lakh ₹20.77 Lakh
Depreciation & Amortisation ₹40.26 Lakh ₹31.83 Lakh ₹39.15 Lakh ₹38.08 Lakh ₹31.65 Lakh ₹31.26 Lakh ₹33.48 Lakh ₹28.17 Lakh
Other Expenses ₹37.51 Lakh ₹1.22 Cr ₹1.27 Cr ₹1.73 Cr ₹1.31 Cr ₹2.36 Cr ₹1.9 Cr ₹1.35 Cr
Total Expenses ₹4.6 Cr ₹4.46 Cr ₹4.9 Cr ₹4.77 Cr ₹5.12 Cr ₹5.24 Cr ₹5.54 Cr ₹5.79 Cr
Profit Before Exceptional Items & Tax ₹86.58 Lakh -₹60.78 Lakh ₹26.03 Lakh ₹6.97 Lakh ₹10.18 Lakh ₹16.05 Lakh ₹10.77 Lakh ₹49.57 Lakh
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹86.58 Lakh -₹60.78 Lakh ₹26.03 Lakh ₹6.97 Lakh ₹10.18 Lakh ₹16.05 Lakh ₹10.77 Lakh ₹49.57 Lakh
Total Tax Expense ₹30.33 Lakh -₹44.01 Lakh ₹25.14 Lakh ₹4.86 Lakh -₹5.01 Lakh ₹10.83 Lakh ₹10.08 Lakh ₹12.78 Lakh
Net Profit ₹56.25 Lakh -₹16.77 Lakh ₹89,000 ₹2.11 Lakh ₹15.19 Lakh ₹5.22 Lakh ₹69,000 ₹36.79 Lakh
Other Comprehensive Income -₹2.11 Lakh ₹6.83 Lakh -₹24,000 ₹24,000 -₹62,000 ₹26,000 ₹25,000 ₹27,000
Total Comprehensive Income ₹54.14 Lakh -₹9.94 Lakh ₹65,000 ₹2.35 Lakh ₹14.57 Lakh ₹5.48 Lakh ₹94,000 ₹37.06 Lakh
EBITDA (computed) ₹1.34 Cr -₹19.78 Lakh ₹73.2 Lakh ₹55.14 Lakh ₹49.73 Lakh ₹59.35 Lakh ₹56.51 Lakh ₹98.51 Lakh
Basic EPS ₹1.11 ₹-0.33 ₹0.02 ₹0.04 ₹0.30 ₹0.10 ₹0.01 ₹0.73
Diluted EPS ₹1.11 ₹-0.33 ₹0.02 ₹0.04 ₹0.30 ₹0.10 ₹0.01 ₹0.73
Latest 8 quarters shown.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Beryl Drugs Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Beryl Drugs Limited

As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 27.48%, retail and other public shareholders hold 72.52% of Beryl Drugs Limited. The company had 7,349 shareholders on record.

Promoters: 27.48%Retail & Others: 72.52%
Mar 2026
QUARTER
27.48% Promoters
72.52% Retail & Others
Promoter holding - history
Now 27.48% · Mar 2026High 27.48% · Mar 2026Low 26.38% · Jun 2023
25%26%27%28%29%Jun 2023Dec 2023Jun 2024Dec 2024Jun 2025Dec 2025Jun 2023: 26.38%Sep 2023: 26.38%Dec 2023: 26.38%Mar 2024: 26.38%Jun 2024: 26.38%Sep 2024: 26.38%Dec 2024: 26.38%Mar 2025: 26.38%Jun 2025: 26.38%Sep 2025: 26.38%Dec 2025: 26.38%Mar 2026: 27.48%26.38%27.48%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters27.48%26.38%26.38%26.38%26.38%26.38%
Public72.52%73.62%73.62%73.62%73.62%73.62%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024
Promoters27.48%26.38%26.38%
Public72.52%73.62%73.62%
Promoter change (YoY, %pts)+1.10+0.00-

Charges & Borrowings of Beryl Drugs Limited

Open charges
₹5.75 Cr
Satisfied charges
₹7.09 Cr
Breakdown by lending institutions
Others₹5.75 Cr
Latest charge details
DateLenderAmountStatus
27 Jun 2024 Others ₹1.75 Cr Open
20 Mar 2023 Others ₹1.15 Cr Open
18 Mar 1997 Others ₹2.85 Cr Open
16 May 2024 Others ₹45 Lakh Satisfied
12 Jun 2020 Others ₹45 Lakh Satisfied

Total charge records: 12 View all charges

Employees and EPFO Compliance at Beryl Drugs Limited

Beryl Drugs Limited has a workforce of 22 employees as of Apr 06, 2024.

Employee count
22
Active EPFO establishments
1
Employee growth
4.76%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Beryl Drugs Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Beryl Drugs Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Beryl Drugs Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Beryl Drugs Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Beryl Drugs Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Beryl Drugs Limited

MSME Payment Delays by Beryl Drugs Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Beryl Drugs Limited

Subsidiaries & Group Companies of Beryl Drugs Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Beryl Drugs Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Beryl Drugs Limited

MCA Filings & Documents of Beryl Drugs Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Beryl Drugs Limited

Directors
24 Jan 2026
Kamlesh Gupta was appointed as a Company Secretary on 24 Jan 2026 & has been associated with this company since 5 months 15 days.
Directors
03 Jan 2026
Shailendra Pathak was appointed as a Additional Director on 03 Jan 2026 & has been associated with this company since 6 months 6 days.
Directors
03 Jan 2026
Neha Sarda was appointed as a Additional Director on 03 Jan 2026 & has been associated with this company since 6 months 6 days.
Activity
30 Sep 2025
Beryl Drugs Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
15 Apr 2025
A charge registered on 16 May 2024 via Charge ID 100930830 with Others was fully satisfied on 15 Apr 2025.
Activity
31 Mar 2025
Beryl Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Gwalior.

Frequently Asked Questions about Beryl Drugs Limited

Beryl Drugs Limited is an active public limited company in the pharma sector based in Indore, Madhya Pradesh, India. It was incorporated on 24 August 1993 (33+ years old) and is registered under CIN L02423MP1993PLC007840. Listed on BSE: 524606. The company has 22 employees.

Beryl Drugs Limited reported revenue of ₹22.55 Cr for FY 2025 (down 17.00% YoY).

The current directors of Beryl Drugs Limited are:

The primary industry of Beryl Drugs Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Beryl Drugs Limited is listed on BSE with code 524606.

Beryl Drugs Limited can be reached at the registered office: 133 Kanchan Bagh, Indore, Madhya Pradesh, India – 452001, or through the website beryldrugs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available